公开(公告)号：US20230078665A1

公开(公告)日：2023-03-16

申请号：US18054346

申请日：2022-11-10

Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.

Inventor： Abraham RUTENBERG ,  Ronny UZANA ,  Michal LOTEM ,  Arthur MACHLENKIN ,  Galit EISENBERG ,  Tamar PERETZ-YABLONSKY ,  Shoshana FRANKENBURG ,  Roni ENGELSTEIN

IPC: C07K14/705 ,  C12N5/0783 ,  A61K38/17 ,  A61K35/17 ,  A61K39/39 ,  A61K39/395 ,  A61K45/06 ,  C07K16/28

Abstract: The present invention is directed to the field of immunotherapy. Specifically, the invention provides compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the invention are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.

公开(公告)号：US20230038224A1

公开(公告)日：2023-02-09

申请号：US17816060

申请日：2022-07-29

Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.

Inventor： Dana Wolf

IPC: G01N33/569

Abstract: The present invention provides biomarkers allowing the diagnosis of symptomatic congenital cytomegalovirus (CMV) infection and in particular to differentiate between symptomatic and asymptomatic infected fetuses, methods of diagnosis of CMV using said biomarkers, diagnostic kits comprising thereof, and use of the kits and methods of diagnosing fetuses infected with a symptomatic congenital cytomegalovirus (CMV).

公开(公告)号：US11530251B2

公开(公告)日：2022-12-20

申请号：US16417048

申请日：2019-05-20

Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD

Inventor： Abraham Rutenberg ,  Ronny Uzana ,  Michal Lotem ,  Arthur Machlenkin ,  Galit Eisenberg ,  Tamar Peretz-Yablonsky ,  Shoshana Frankenburg ,  Roni Engelstein

IPC: C07K14/705 ,  A61K38/17 ,  A61K35/17 ,  A61P35/00 ,  C12N5/0783 ,  A61K39/39 ,  A61K39/395 ,  A61K45/06 ,  C07K16/28 ,  A61K39/00

Abstract: The present invention is directed to the field of immunotherapy. Specifically, the invention provides compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the invention are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.

公开(公告)号：US20220347203A1

公开(公告)日：2022-11-03

申请号：US17622224

申请日：2020-06-23

Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.

Inventor： Michal Lotem ,  Emma Hajaj ,  Galit Eisenberg

IPC: A61K31/712 ,  C12N15/113 ,  A61K35/17

Abstract: The invention relates to nucleic acid agents modulating the expression of SLAMF6 isoforms, compositions comprising same and methods for their use in immunomodulation. Specifically, provided are splice-switching oligonucleotides and constructs useful in cancer immunotherapy.

公开(公告)号：US11478453B2

公开(公告)日：2022-10-25

申请号：US16318468

申请日：2017-07-20

Applicant: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.

Inventor： Iris Lavon Ben Moshe ,  Tamar Canello Avramovitch

IPC: A61K31/4166 ,  A61K31/175 ,  A61K31/517 ,  G01N33/574 ,  A61P35/00 ,  A61K45/06 ,  G01N33/50

Abstract: The invention relates to the treatment of brain tumors, specifically to improved therapy for glioblastoma utilizing specific endocrine modulators and drug combinations. The compositions and uses thereof according to the invention employ androgen receptor (AR) inhibitors, either alone or in combination with receptor tyrosine kinase inhibitors and/or chemotherapeutic agents. According to certain advantageous embodiments, the use of the AR inhibitor enzalutamide, optionally in combination with epidermal growth factor receptor inhibitors such as erlotinib and alkylating agents such as carmustine and temozolomide, is contemplated.

公开(公告)号：US11466323B2

公开(公告)日：2022-10-11

申请号：US16630593

申请日：2018-07-13

Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. ,  HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.

Inventor： Yuval Dor ,  Ruth Shemer ,  Benjamin Glaser ,  Judith Magenheim

IPC: C12Q1/6876 ,  C12Q1/6827 ,  C12Q1/686 ,  C12Q1/6869

Abstract: A digital droplet PCR method of analyzing the methylation status of methylation sites of a double-stranded DNA molecule which comprises at least two methylation sites per single strand of the double-stranded DNA molecule is disclosed.

公开(公告)号：US20220233477A1

公开(公告)日：2022-07-28

申请号：US17618541

申请日：2020-06-11

Applicant: Hadasit Medical Research Services and Development Ltd.

Inventor： Benjamin Eithan REUBINOFF ,  Etti BEN-SHUSHAN

IPC: A61K31/166 ,  C12N5/079 ,  A61P9/10 ,  A61P37/06 ,  A61P25/28

Abstract: A method of generating human mature oligodendrocytes is disclosed. The method comprises contacting a cell population which comprises human pre-oligodendrocytes with an inhibitor of the MAPK/ERK pathway under conditions that allow the pre-oligodendrocytes to differentiate into mature oligodendrocytes. Use of the MAPK/ERK pathway inhibitor for treating diseases is also disclosed.

公开(公告)号：US20220225612A1

公开(公告)日：2022-07-21

申请号：US17531957

申请日：2021-11-22

Applicant: NOBIO Ltd. ,  Hadasit Medical Research Services and Development Ltd.

Inventor： Nathan Zaltsman ,  Ervin Itzhak Weiss ,  Nurit Beyth

IPC: A01N33/12 ,  A61K47/69 ,  A61K6/80 ,  A01N25/12 ,  A61K8/25 ,  A61K8/41 ,  C08K9/04

Abstract: The present invention relates to anti-microbially active micro and nanoparticles, compositions comprising same, and use thereof for inhibiting bacterial growth and biofilm formation on surfaces or devices, e.g., dental surfaces or devices. The present invention further discloses methods of making such anti-microbially active micro or nanoparticles.

公开(公告)号：US20220119474A1

公开(公告)日：2022-04-21

申请号：US17431867

申请日：2020-02-19

Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. ,  HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.

Inventor： Rachel BAR-SHAVIT ,  Chaim GILON ,  Amnon HOFFMAN

IPC: C07K14/705 ,  A61P35/00

Abstract: The present invention provides peptides derived from the cytoplasmic region of protease-activated receptors 4 (PAR4) as well as analogs and cyclic analogs, such as backbone cyclic analogs, of these peptides. Pharmaceutical compositions comprising said peptides, analog, cyclic analogs and well as conjugates thereof are provides as well. The peptides, analogs and conjugates of the present invention and pharmaceutical composition comprising thereof have several uses including treating cancer and inhibiting interactions between PARs and protein comprising PH-domain.

公开(公告)号：US11241147B2

公开(公告)日：2022-02-08

申请号：US14891611

申请日：2014-05-16

Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. ,  Hadasit Medical Research Services and Development Ltd.

Inventor： Itai Hayut ,  Elchanan Fried ,  Yaakov Nahmias ,  Tommy Weiss-Sadan ,  Ariel Shrem

IPC: A61B1/06 ,  A61B1/00 ,  A61B1/267 ,  A61M16/04 ,  A61B1/04

Abstract: A guided tracheal intubation system using an autonomous modulated light source, outputting modulated illumination at a constant level, and externally applied to the subject's larynx region. An optical imaging system receives a video stream from within the subject's throat, including modulated illumination from the subject's trachea. A display control system performs signal processing on the modulated content of the images, and outputs frames of those images in which the intensity level of illumination from the trachea can be controlled without any need to change the illumination output from the modulated light source. The light source has no connection with the rest of the system, and need contain no more than a battery, a power supply circuit and a light source. It can therefore be of low cost and can be made disposable, such as in the form of an adhesive patch applied to the subject's neck.